Our next generation AI-driven drug discovery system
Our Pipeline
At Katamaran Industries, we are harnessing the power of our AI-driven super engine to build a cutting-edge pipeline of potential first-in-class.
We focus on indications with high unmet need, including oncology and rare disease.
Our Platform
KAPA 03 : KAtamaran’s Predictive AI engine (KAPA ™)
KAPA 03 is our proprietary fine-tuned foundation model for oncology, pre-trained on massive multi-omic datasets to decode the "grammar" of oncology—predicting drug efficacy, resistance mechanisms, and patient subpopulation responses.
The Ex-Vivo Platform: Biological Grounding
● Multimodal Data Generation: Integrated phenotypic imaging and molecular profiling for a holistic view of drug response.
● 3D Patient-Derived Organoids (PDOs): Precision-aligned screening for primary clinical response validation.
The Result: A closed-loop system where real human biology continuously evolves KAPA 03 into a predictive powerhouse for drug discovery.
We actively fine-tune KAPA 03 using high-fidelity, human-relevant data from our Ex-Vivo Tissue Assay Platform. This "grounds" our AI in real-world biology through:
Synthesizability Gatekeeping: Ensuring every AI-generated lead is chemically viable for rapid Wet Lab validation.
Multi-Parameter Optimization (MPO): Simultaneously balancing binding energy with clinical-grade bioavailability and selectivity.
Atomic-Scale Refinement: Leveraging CHARMM36 force fields and dual-algorithmic mapping to ground interactions in biologically accurate dynamics.
Technical Workflow
Reinforcement Learning (RLHB): Using data from our Ex-Vivo Platform to continuously evolve generative logic.
●Engineered Micro-Tumors: Mechanistic studies and immune co-culture analysis in controlled environments.
AI Engine 2 : Katamaran’s Generative AI for
Molecular Advancement(GAMA™)
GAMA™ is Katamaran’s proprietary engine for de novo design, engineered to bridge the gap between high-affinity discovery and clinical developability.
Together, KAPA™ and GAMA™ form Katamaran’s Twin AI Engines—uniting prediction and generation to power the future of precision drug discovery
Over time, GAMA™ becomes a self-learning discovery engine, accelerating hit-to-lead timelines and expanding therapeutic innovation across oncology and rare diseases
Through this closed feedback loop, GAMA™ continuously evolves designing, optimizing,and prioritizing new molecules and biologics guided by human-relevant data.
Built on large, curated chemical, bioactivity, and multi-omic datasets, GAMA™ learns the
underlying chemical grammar, structure–activity relationships, and biological response patterns that drive therapeutic efficacy
Computational Lab
●Trial-on-Chip Assays: Microfluidic systems providing translational validation and clinical readiness.
Physics-Based Generative Design
Technical Workflow
In industry-standard testing on challenging targets like PD-L1 (5N2F), GAMA™ independently identified leads that achieved superior binding affinities to published reference hits while maintaining absolute, zero-violation drug-likeness profiles.
Katamaran is establishing a next-generation Wet Lab facility that integrates 3D patient derived tumor systems, microfluidic Lab on Chip technologies, and AI-driven analytics.
Currently in development, the lab will serve as the experimental foundation of Katamaran’s precision oncology platform. where patient biology, automation, and machine learning converge.
///////////////
Wet Lab
Key capabilities under build-out include:
01
02
03
04
05
Patient-Derived Organoids (PDOs)/ Mini-Tumors
Engineered Organoids
Organotypic Tumor Slices
Lab-on-Chip (LoC)
Trial-on-Chip (ToC)
High-fidelity ex-vivo validation models preserving full tumor architecture.
Miniaturized microfluidic assays that recreate the tumor microenvironment under controlled perfusion and gradients, enabling dynamic studies of drug action and immune-tumor interactions.
A miniature, clinical-trial-like platform using patient-matched tumor slices to validate drug responses, optimize dosing, and predict responders before clinical trials.
Currently in development, the lab will serve as the experimental foundation of Katamaran’s precision oncology platform. where patient biology, automation, and machine learning converge.
Key capabilities under build-out include:
PDOs enhanced with stromal, endothelial, or immune components and CRISPR-based edits.
Mini-tumors representing individual patient genetics and heterogeneity.
Mini-tumors representing individual patient genetics and heterogeneity.
Patient-Derived Organoids (PDOs)/ Mini-Tumors
01
PDOs enhanced with stromal, endothelial, or immune components and CRISPR-based edits.
Engineered Organoids
02
High-fidelity ex-vivo validation models preserving full tumor architecture.
Organotypic Tumor Slices
03
Miniaturized microfluidic assays that recreate the tumor microenvironment under controlled perfusion and gradients, enabling dynamic studies of drug action and immune-tumor interactions
Lab-on-Chip (LoC)
04
A miniature, clinical-trial-like platform using patient-matched tumor slices to validate drug responses, optimize dosing, and predict responders before clinical trials.
Trial-on-Chip (ToC)
05
This facility will enable AI-linked 3D drug screening, immune-oncology co-cultures, and predictive response modeling, bridging discovery and clinic with human-relevant data.
Our goal is to launch the first functional LoC and ex-vivo assay units within the next development phase.
This facility will enable AI-linked 3D drug screening, immune-oncology co-cultures, and predictive response modeling, bridging discovery and clinic with human-relevant data.
Our goal is to launch the first functional LoC and ex-vivo assay units within the next development phase
Data Showing Validation of our Ex-Vivo Platform for Targeted Drug Assays.
Data Showing Validation of our Ex-Vivo Platform for Targeted Drug Assays.
Currently in development, the lab will serve as the experimental foundation of Katamaran’s precision oncology platform. where patient biology, automation, and machine learning converge.
Data Showing Validation of our Ex-Vivo Platform for Targeted Drug Assays.
Automated Wet Lab Workflows (Planned Development)
Katamaran is planning the development of a next-generation automated wet lab integrating robotics, sterile modular systems, and AI-driven workflow orchestration to reduce manual handling, variability, and human error in complex biological experiments.
The envisioned setup will feature enclosed, sterile automation modules connected by robotic or conveyor-based transfer systems, enabling culture plates and samples to move seamlessly through stages of cell seeding, compound dosing, incubation, imaging, and analysis.
The planned automation stack will include:
01
02
03
04
Robotic liquid handling and dispensing systems for precise and reproducible multi-condition screening
Automated incubation and imaging units for consistent environmental control and real-time data acquisition
AI-based workflow orchestration software to coordinate assays, monitor performance, and ensure traceability
Integrated data pipelines linking results directly with KAPA™ and GAMA™ for continuous model improvement
Automation
Automated Wet Lab Workflows (Planned Development)
By minimizing manual intervention and experimental error, Katamaran aims to establish a high-throughput, continuously learning research ecosystem that enhances data reliability and accelerates translation from prediction to proof-of-concept.
Katamaran is planning the development of a next-generation automated wet lab integrating robotics, sterile modular systems, and AI-driven workflow orchestration to reduce manual handling, variability, and human error in complex biological experiments.
The envisioned setup will feature enclosed, sterile automation modules connected by robotic or conveyor-based transfer systems, enabling culture plates and samples to move seamlessly through stages of cell seeding, compound dosing, incubation, imaging, and analysis.
The planned automation stack will include:
01
Robotic liquid handling and dispensing systems for precise and reproducible multi-condition screening
02
Automated incubation and imaging units for consistent environmental control and real-time data acquisition
03
AI-based workflow orchestration software to coordinate assays, monitor performance, and ensure traceability
04
Integrated data pipelines linking results directly with KAPA™ and GAMA™ for continuous model improvement
Once implemented, these automated workflows will form a closed, self-learning discovery cycle, where AI designs, automation executes, and biology validates
By minimizing manual intervention and experimental error, Katamaran aims to establish a high-throughput, continuously learning research ecosystem that enhances data reliability and accelerates translation from prediction to proof-of-concept.
Once implemented, these automated workflows will form a closed, self-learning discovery cycle, where AI designs, automation executes, and biology validates
We’re looking for collaborators, investors, and visionary scientists. Reach out and be part of the mission.
Quick Links
Our Address
India :
Unit, #603, 6th floor, Sigmasoft tech park, Gamma block, Whitefeild, Bengaluru, Karnataka, 560066
US :
Unit 419,180 talmadge rd, Edison nj 08817
UK :
41 Clooney Terrace, Londonderry, Northern Ireland, BT47 6AP
Mail :
Follow Us
